In the pharmaceutical mergers and acquisitions (M&A) market of 2025, the landscape resembled a powder keg with a delayed fuse. While Johnson & Johnson's staggering $14.6 billion deal at the beginning of the year was startling, it merely lit the fuse.

The true explosion occurred toward the end of the year, with eight of the year’s top ten deals taking place in the second half, six of which were crammed into the fourth quarter. This pattern of a "cold start and heated finish" was closely tied to the macro-environment and political uncertainties facing the industry.

Arda Ural, head of U.S. life sciences at EY, echoed early market observations, noting that political uncertainty at the start of the year had led to a pause in deal-making.

Uncertainty was not confined to the political arena. In 2025, the FDA experienced a massive wave of personnel changes and resignations, causing many pharmaceutical executives to temporarily put their M&A plans on hold. As the industry gained a clearer understanding of the new regulatory and pricing environment, the M&A market truly heated up in the second half of the year.

Examining the pharmaceutical M&A ledger for 2025, the most notable feature was not a surge in the number of deals but a leap in their quality.

According to EY data, although the total volume of deals declined, the average value per transaction soared from approximately $1 billion in 2024 to $1.9 billion in 2025—nearly doubling. This indicates that buyers are no longer pursuing a broad-scatter approach but are instead concentrating capital on assets they deem "strategic necessities."

From the perspective of therapeutic areas, a striking shift is underway. Oncology, which has long dominated the landscape, was surpassed for the first time in years.

Ural also revealed that in the first ten months of 2025, M&A activity in the central nervous system and neuroscience fields had already exceeded that in oncology. In other words, the industry has rekindled confidence in neuroscience, viewing these historically high-risk areas as transforming into commercially viable growth opportunities.

The rise of Chinese biotechnology companies is another trend that cannot be ignored.

Of the deals announced in 2025, approximately 35% originated from China, underscoring the country's increasingly vital role in the global pharmaceutical innovation ecosystem. These transactions span multiple cutting-edge fields, from Antibody-Drug Conjugates (ADCs) to cell therapies, marking China's evolution from a "follower" to a "contributor."

The 2025 M&A market has been filled with dramatic showdowns and strategic moves.

In terms of deal value, Johnson & Johnson undoubtedly emerged as the year's biggest buyer. Its $14.6 billion acquisition of Intra-Cellular Therapies not only stood as the highest-value deal of the year but also underscored its firm commitment to the neuroscience field.

Novartis followed closely, acquiring Avidity Biosciences for $12 billion to gain access to its Antibody Oligonucleotide Conjugates (AOC) platform for the precise delivery of RNA therapies. Merck & Co. strategically expanded its portfolio by acquiring Verona Pharma and Cidara Therapeutics, targeting both the respiratory and antiviral fields.

Looking at the distribution across therapeutic areas, deals in neuroscience were particularly noteworthy.

Beyond J&J's landmark transaction, Novartis's acquisition of Avidity Biosciences also focused on rare neuromuscular diseases. These deals collectively reaffirmed the regained confidence of major pharmaceutical companies in neuroscience.

The cell and gene therapy space, however, showed a split trend. On one hand, companies like Takeda, Roche, and Novo Nordisk scaled back or exited their investments in this field. On the other hand, Bristol Myers Squibb (BMS) bucked the trend, investing $1.5 billion to acquire Orbital Therapeutics, reinforcing its presence in cell therapies.

Yet, if one had to name the most sought-after therapeutic area of 2025, it would undoubtedly be metabolic diseases. The defining event in this field was the fierce bidding war between Pfizer and Novo Nordisk for Metsera.

The bidding war began last September when Pfizer signed a merger agreement with Metsera to acquire it for $4.9 billion in cash plus $2.4 billion in milestone payments. The deal was pending only regulatory approval, and the market generally believed Metsera was already in Pfizer's grasp.

However, the situation changed abruptly in late October. Novo Nordisk suddenly presented Metsera with a competitive acquisition proposal valued at $8.5 billion, consisting of $6 billion in upfront payments and $2.5 billion in milestone payments. This offer, approximately $1.23 billion higher than Pfizer's previous $7.3 billion proposal, immediately altered the dynamics of the game.

Metsera's board promptly determined that Novo Nordisk's offer constituted a "superior proposal" and notified Pfizer of its right to terminate the existing agreement under the terms of the merger agreement.

Faced with this unexpected challenge, Pfizer took aggressive legal action. Pfizer CEO Albert Bourla publicly criticized Novo Nordisk's offer as "illusory" and in violation of antitrust laws, arguing it did not constitute a superior proposal. Pfizer filed its second lawsuit against Novo Nordisk and Metsera, accusing its rival of violating competition laws through its acquisition attempt and seeking a court injunction to block Novo Nordisk's proposal.

The legal battle lasted for weeks, with both sides fiercely contending in court and the market. Ultimately, Pfizer raised its bid to the $10 billion level to successfully defend its highly coveted acquisition.

Why was Metsera so highly sought after? This biotech company, founded just three years ago with only 81 employees, derives its value from a pipeline targeting various receptors such as GLP-1 and the gut hormone amylin, particularly its once-monthly treatment under development.

On December 31, 2025, Metsera registered a Phase III clinical trial, VESPER-4, on ClinicalTrials.gov for its ultra-long-acting GLP-1 receptor agonist MET097 in the treatment of obesity or overweight. The study is set to enroll 3,500 participants, with preliminary completion expected by September 2027.

Against the backdrop of the weight-loss drug market projected to reach $95 billion by 2030, assets with greater differentiation are increasingly becoming the focus of fierce competition among industry giants.

The surge in pharmaceutical M&A activity in 2025 is no coincidence but the result of multiple converging factors. The most fundamental driver is the imminent "patent cliff."

In the coming years, global pharmaceutical companies face the expiration of patents for drugs valued at approximately $300 billion, including blockbuster products such as the anticoagulant Eliquis and the "king of drugs," Keytruda.

Even if Merck succeeds in launching a new subcutaneous injection formulation for Keytruda, it can only delay its sales decline. To fill the revenue gap left by patent expirations, acquiring mature pipelines through M&A has become the optimal solution for pharmaceutical companies.

At the same time, ample financial resources have provided solid support for M&A. Data from Truist Securities show that the current balance sheet capacity of global pharmaceutical companies stands at around $500 billion, while Stifel estimates suggest that the industry's total available funds could reach as high as $1.2 trillion.

This capital-rich environment has enabled pharmaceutical companies to pursue larger and more strategic transactions, even amid macroeconomic and regulatory uncertainties.

The scarcity of high-quality assets has further intensified M&A activity. The latest analysis from McKinsey reveals that there are currently only 17 "unencumbered Phase III clinical assets" available on the global market. This number continues to shrink as recent deals are finalized.

This scarcity is forcing pharmaceutical companies to shift their focus to earlier-stage assets. Currently, over half of M&A transactions are concentrated in the early clinical stages.

Changes in the policy environment have also provided a tailwind for M&A activity. As the Federal Reserve lowers interest rates, the low-rate environment has made pharmaceutical companies more inclined to invest in acquisitions to enhance asset value rather than leaving cash idle on their balance sheets.

Following the active conclusion of the M&A market in 2025, the industry's focus has naturally shifted to 2026. Insiders predict that 2026 may become a "breakthrough year" for pharmaceutical M&A.

Goldman Sachs even suggests that 2026 could set a record for M&A transaction values. This optimistic outlook is based on several key factors: strong corporate balance sheets, accumulated strategic needs, and the structural pressures facing the industry.

In terms of deal types, "bolt-on acquisitions" in the $5-10 billion range are expected to become mainstream. Pharmaceutical companies are no longer solely focused on large-scale acquisitions but are increasingly turning to multiple smaller transactions to diversify risks and enrich their pipelines.

This strategy allows pharmaceutical companies to build advantages across multiple therapeutic areas or technology platforms while avoiding significant risks associated with the failure of a single large deal.

Arun Swaminathan, CEO of Coya Therapeutics, explicitly stated, "From 2026 to 2027, we will witness a major M&A season." The rationale behind this prediction remains the same: the imminent patent cliff crisis faced by global pharmaceutical companies and the scarcity of high-quality assets.

In terms of therapeutic areas, obesity and metabolic diseases will continue to be a focal point, but competition has shifted from "casting a wide net" to "targeted breakthroughs."

In 2024, driven by the first wave of weight-loss drugs led by Novo Nordisk and Eli Lilly, almost any asset related to obesity treatment was highly sought after by the pharmaceutical industry. Now, however, companies are paying more attention to specific patient populations and unmet needs. For example, weight-loss drugs that do not affect muscle mass are likely to be more favored.

The neuroscience field, with its "high-risk, high-reward" characteristics, will also attract more pharmaceutical companies. Meanwhile, the oncology field, due to market fragmentation, is gradually losing its appeal as a source of "blockbuster drugs."

AI is poised to play an increasingly important role in M&A decision-making. Philip Poulidis, CEO of ODAIA, noted that buyers now not only evaluate the asset itself but also consider a company’s commercial capabilities.

With the support of AI, small biotech companies can strategically position themselves in the market like large pharmaceutical firms. This ability to "punch above their weight" will become a crucial factor in buyers' assessments. Additionally, pharmaceutical companies equipped with AI infrastructure can achieve synergies with acquisition targets more swiftly, a key advantage in large-scale M&A deals.

The capital feast will eventually come to an end, but the pace of industry innovation will not stop. The M&A surge in 2025 reflects a collective choice by pharmaceutical companies to address the pressures of innovation and commercial challenges.

In 2026, as the $300 billion patent cliff looms even closer, this grand M&A spectacle may have only just begun.